Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANUEL E RODRIGUEZ

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1356399307
CMS profile
197176
Location
BRADENTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$61,846.03

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANUEL E RODRIGUEZ

NPI 1356399307 · CMS profile ID 197176

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BRADENTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $61,846.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $114.0908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964646 CMS
Ardelyx, Inc. $17.7008/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146704266 CMS
ABBVIE INC. $21.1308/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964642 CMS
ABBVIE INC. $14.9808/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964644 CMS
AIMMUNE THERAPEUTICS, INC. $16.1808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146976214 CMS
Lilly USA, LLC $14.7908/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135149494 CMS
Regeneron Healthcare Solutions, Inc. $20.4807/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148375 CMS
Phathom Pharmaceuticals, Inc. $108.5306/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151117265 CMS
Phathom Pharmaceuticals, Inc. $124.4606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151117263 CMS
Janssen Biotech, Inc. $15.5506/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078401744 CMS
AIMMUNE THERAPEUTICS, INC. $12.8106/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146983459 CMS
GENZYME CORPORATION $41.7805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139939147 CMS
Regeneron Healthcare Solutions, Inc. $27.4705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148373 CMS
AIMMUNE THERAPEUTICS, INC. $22.4005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146975798 CMS
ABBVIE INC. $13.2405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964640 CMS
Gilead Sciences, Inc. $22.4104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133780356 CMS
Gilead Sciences, Inc. $33.3704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133780358 CMS
Gilead Sciences, Inc. $74.3004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133780360 CMS
Gilead Sciences, Inc. $262.9804/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864792 CMS
Gilead Sciences, Inc. $640.2004/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864794 CMS
Gilead Sciences, Inc. $1,724.8804/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864796 CMS
Regeneron Healthcare Solutions, Inc. $22.1604/15/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148371 CMS
Gilead Sciences, Inc. $48.4504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133780354 CMS
Regeneron Healthcare Solutions, Inc. $38.7703/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148369 CMS
ABBVIE INC. $14.1803/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964638 CMS
ABBVIE INC. $28.7703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964636 CMS
Phathom Pharmaceuticals, Inc. $19.0703/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151117261 CMS
ABBVIE INC. $28.1102/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964634 CMS
ABBVIE INC. $14.7502/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964632 CMS
AIMMUNE THERAPEUTICS, INC. $13.7402/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147017027 CMS
Merck Sharp & Dohme LLC $18.1602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141621128 CMS
ABBVIE INC. $22.9001/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964630 CMS
AIMMUNE THERAPEUTICS, INC. $76.9901/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147017129 CMS
ABBVIE INC. $118.9301/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964628 CMS
ABBVIE INC. $24.1801/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105964626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $922.25 31
PY2020 $102.78 7
PY2021 $426.12 26
PY2022 $1,261.84 48
PY2023 $761.51 36
PY2024 $61,846.03 85
PY2025 $40,388.99 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $888,567.13 405
PY2024 Principal investigator $456,119.82 213
PY2023 Principal investigator $216,373.00 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

405 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $32,616.00 12/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALIST
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175345642
Principal investigator 1 Janssen Research & Development, LLC $32,616.00 12/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALIST
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC No dispute reported 06/30/2026 1175345652
Principal investigator 1 Madrigal Pharmaceuticals $2,905.70 12/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254720
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254725
Principal investigator 1 F. Hoffmann-La Roche AG $86.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606002
Principal investigator 1 F. Hoffmann-La Roche AG $250.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606007
Principal investigator 1 F. Hoffmann-La Roche AG $2,864.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606033
Principal investigator 1 F. Hoffmann-La Roche AG $86.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606041
Principal investigator 1 F. Hoffmann-La Roche AG $250.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606045
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254249
Principal investigator 1 Madrigal Pharmaceuticals $2,277.52 12/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254253
Principal investigator 1 Madrigal Pharmaceuticals $13,279.00 12/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254223
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 12/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254227
Principal investigator 1 Madrigal Pharmaceuticals $1,314.00 12/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254231
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254235
Principal investigator 1 Madrigal Pharmaceuticals $100.00 12/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254240
Principal investigator 1 Eli Lilly and Company $1,621.26 12/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187881182
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187881976
Principal investigator 1 Bausch Health US, LLC $150.00 12/16/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840072
Principal investigator 1 Madrigal Pharmaceuticals $490.00 12/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254143
Principal investigator 1 Genentech, Inc. $2,500.00 12/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606169
Principal investigator 1 Gilead Sciences, Inc. $80.64 12/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209334
Principal investigator 1 Gilead Sciences, Inc. $30.00 12/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209519
Principal investigator 1 F. Hoffmann-La Roche AG $28.69 12/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606005
Principal investigator 1 Madrigal Pharmaceuticals $710.00 12/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253810
Principal investigator 1 Gilead Sciences, Inc. $43.50 12/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209358
Principal investigator 1 Gilead Sciences, Inc. $60.00 12/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209389
Principal investigator 1 Madrigal Pharmaceuticals $18,340.00 12/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253682
Principal investigator 1 Madrigal Pharmaceuticals $490.00 12/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248253614
Principal investigator 1 Gilead Sciences, Inc. $201.00 12/05/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204696
Principal investigator 1 F. Hoffmann-La Roche AG $15.90 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606011
Principal investigator 1 F. Hoffmann-La Roche AG $50.13 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606016
Principal investigator 1 F. Hoffmann-La Roche AG $250.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606018
Principal investigator 1 F. Hoffmann-La Roche AG $172.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606022
Principal investigator 1 F. Hoffmann-La Roche AG $172.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606026
Principal investigator 1 F. Hoffmann-La Roche AG $400.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606029
Principal investigator 1 F. Hoffmann-La Roche AG $29.28 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606037
Principal investigator 1 F. Hoffmann-La Roche AG $22.55 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606049
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253302
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253306
Principal investigator 1 Madrigal Pharmaceuticals $2,014.33 12/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253311
Principal investigator 1 Madrigal Pharmaceuticals $10,413.90 12/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253298
Principal investigator 1 Gilead Sciences, Inc. $67.00 12/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204686
Principal investigator 1 Madrigal Pharmaceuticals $7,861.00 11/27/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253050
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 11/27/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253055
Principal investigator 1 Madrigal Pharmaceuticals $400.00 11/27/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253059
Principal investigator 1 Genentech, Inc. $258.00 11/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606158
Principal investigator 1 Genentech, Inc. $2,670.00 11/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606162
Principal investigator 1 Genentech, Inc. $2,776.00 11/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606166
Principal investigator 1 Madrigal Pharmaceuticals $4,291.85 11/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252819
Principal investigator 1 Genentech, Inc. $4,495.00 11/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606149
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 11/19/2025 Non-covered Recipient Entity
FLORIDA RESEARCH INSTITUTE
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177742
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 11/19/2025 Non-covered Recipient Entity
FLORIDA RESEARCH INSTITUTE
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177747
Principal investigator 1 Eli Lilly and Company $12,640.00 11/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187881974
Principal investigator 1 Genentech, Inc. $6,079.00 11/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606153
Principal investigator 1 Gilead Sciences, Inc. $1,275.00 11/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209501
Principal investigator 1 Madrigal Pharmaceuticals $2,277.52 11/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252372
Principal investigator 1 Madrigal Pharmaceuticals $1,314.00 11/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252322
Principal investigator 1 Gilead Sciences, Inc. $4,166.10 11/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209535
Principal investigator 1 Madrigal Pharmaceuticals $1,314.00 11/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252286
Principal investigator 1 Madrigal Pharmaceuticals $1,314.00 11/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252290
Principal investigator 1 Madrigal Pharmaceuticals $75.00 11/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252294
Principal investigator 1 Madrigal Pharmaceuticals $6,020.00 11/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252298
Principal investigator 1 Genentech, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606123
Principal investigator 1 Genentech, Inc. $11,600.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606127
Principal investigator 1 Genentech, Inc. $250.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606131
Principal investigator 1 Genentech, Inc. $5,914.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606137
Principal investigator 1 Genentech, Inc. $123.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606145
Principal investigator 1 Gilead Sciences, Inc. $2,910.60 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204706
Principal investigator 1 Gilead Sciences, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209424
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209542
Principal investigator 1 Gilead Sciences, Inc. $650.00 10/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206783
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658656
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658658
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658660
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658662
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658664
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209317
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209341
Principal investigator 1 Gilead Sciences, Inc. $230.50 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209380
Principal investigator 1 Gilead Sciences, Inc. $87.00 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209432
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209457
Principal investigator 1 Gilead Sciences, Inc. $200.00 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209480
Principal investigator 1 Gilead Sciences, Inc. $143.50 10/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209487
Principal investigator 1 Madrigal Pharmaceuticals $2,397.39 10/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251763
Principal investigator 1 Madrigal Pharmaceuticals $50.00 10/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251766
Principal investigator 1 Madrigal Pharmaceuticals $75.00 10/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251707
Principal investigator 1 Madrigal Pharmaceuticals $75.00 10/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251712
Principal investigator 1 Madrigal Pharmaceuticals $7,259.00 10/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251717
Principal investigator 1 Madrigal Pharmaceuticals $6,020.00 10/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251721
Principal investigator 1 Madrigal Pharmaceuticals $400.00 10/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251725
Principal investigator 1 Gilead Sciences, Inc. $30.00 10/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206761
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 10/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206773
Principal investigator 1 Boehringer Ingelheim International GmbH $24.14 10/20/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658654
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 10/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209350
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 10/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209394
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209416
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209450
Principal investigator 1 Genentech, Inc. $883.35 10/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606141
Principal investigator 1 Madrigal Pharmaceuticals $1,341.90 10/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251481
Principal investigator 1 Gilead Sciences, Inc. $400.00 10/08/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209407
Principal investigator 1 Madrigal Pharmaceuticals $1,370.00 10/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251303
Principal investigator 1 Madrigal Pharmaceuticals $1,314.00 10/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251307
Principal investigator 1 Madrigal Pharmaceuticals $75.00 10/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251312
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 10/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251316
Principal investigator 1 Genentech, Inc. $142.80 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606119
Principal investigator 1 Gilead Sciences, Inc. $30.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209327
Principal investigator 1 Gilead Sciences, Inc. $150.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209365
Principal investigator 1 Gilead Sciences, Inc. $150.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209372
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209439
Principal investigator 1 Gilead Sciences, Inc. $500.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209466
Principal investigator 1 Gilead Sciences, Inc. $500.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209472
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209494
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209509
Principal investigator 1 Gilead Sciences, Inc. $75.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209527
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250925
Principal investigator 1 Madrigal Pharmaceuticals $75.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250929
Principal investigator 1 Madrigal Pharmaceuticals $75.00 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250933
Principal investigator 1 Madrigal Pharmaceuticals $1,341.90 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250937
Principal investigator 1 Madrigal Pharmaceuticals $1,341.90 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251293
Principal investigator 1 Madrigal Pharmaceuticals $9,403.95 10/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251297
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 10/02/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250921
Principal investigator 1 Bausch Health US, LLC $280.00 09/30/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840067
Principal investigator 1 Gilead Sciences, Inc. $75.00 09/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209259
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 09/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209311
Principal investigator 1 Madrigal Pharmaceuticals $150.00 09/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250742
Principal investigator 1 Boehringer Ingelheim International GmbH $580.75 09/24/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658652
Principal investigator 1 Genentech, Inc. $750.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606115
Principal investigator 1 Gilead Sciences, Inc. $75.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209244
Principal investigator 1 Gilead Sciences, Inc. $60.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209250
Principal investigator 1 Gilead Sciences, Inc. $60.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209274
Principal investigator 1 Gilead Sciences, Inc. $75.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209280
Principal investigator 1 Gilead Sciences, Inc. $75.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209289
Principal investigator 1 Gilead Sciences, Inc. $75.00 09/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209299
Principal investigator 1 Madrigal Pharmaceuticals $2,392.98 09/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250534
Principal investigator 1 Madrigal Pharmaceuticals $75.00 09/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250140
Principal investigator 1 Madrigal Pharmaceuticals $9,403.95 09/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250144
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 09/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209204
Principal investigator 1 F. Hoffmann-La Roche AG $172.00 09/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211606000
Principal investigator 1 Gilead Sciences, Inc. $17,068.50 09/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209264
Principal investigator 1 Madrigal Pharmaceuticals $4,449.68 09/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249888
Principal investigator 1 Madrigal Pharmaceuticals $50.00 09/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249857
Principal investigator 1 Gilead Sciences, Inc. $500.00 09/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206752
Principal investigator 1 GlaxoSmithKline, LLC. $1,864.76 09/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120800
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 09/05/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249748
Principal investigator 1 Gilead Sciences, Inc. $30.00 09/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204654
Principal investigator 1 Gilead Sciences, Inc. $267.00 09/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204668
Principal investigator 1 Madrigal Pharmaceuticals $100.00 09/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249296
Principal investigator 1 Madrigal Pharmaceuticals $1,295.00 09/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249300
Principal investigator 1 Madrigal Pharmaceuticals $400.00 09/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249303
Principal investigator 1 Gilead Sciences, Inc. $30.00 08/27/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204660
Principal investigator 1 F. Hoffmann-La Roche AG $6,318.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211605995
Principal investigator 1 Gilead Sciences, Inc. $100.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206711
Principal investigator 1 Gilead Sciences, Inc. $3,100.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206720
Principal investigator 1 Gilead Sciences, Inc. $575.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206727
Principal investigator 1 Gilead Sciences, Inc. $30.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206735
Principal investigator 1 Gilead Sciences, Inc. $30.00 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206744
Principal investigator 1 Madrigal Pharmaceuticals $2,014.33 08/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249067
Principal investigator 1 Gilead Sciences, Inc. $60.00 08/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209212
Principal investigator 1 Madrigal Pharmaceuticals $15,516.90 08/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248982
Principal investigator 1 Eli Lilly and Company $420.53 08/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187882402
Principal investigator 1 Madrigal Pharmaceuticals $7,259.00 08/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248786
Principal investigator 1 GlaxoSmithKline, LLC. $3,306.29 08/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174916
Principal investigator 1 Bausch Health US, LLC $1,362.44 08/14/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840064
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 08/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248376
Principal investigator 1 Madrigal Pharmaceuticals $4,449.68 08/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248084
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 08/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114504
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120813
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 08/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174920
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 08/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177726
Principal investigator 1 Janssen Research & Development, LLC $2,953.00 07/28/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193314
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 07/28/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193328
Principal investigator 1 Gilead Sciences, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204675
Principal investigator 1 Gilead Sciences, Inc. $1,900.00 07/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206689
Principal investigator 1 Gilead Sciences, Inc. $30.00 07/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206697
Principal investigator 1 Madrigal Pharmaceuticals $12,040.00 07/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247361
Principal investigator 1 Madrigal Pharmaceuticals $300.00 07/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247320
Principal investigator 1 Madrigal Pharmaceuticals $300.00 07/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248247325
Principal investigator 1 Madrigal Pharmaceuticals $9,393.30 07/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248247260
Principal investigator 1 F. Hoffmann-La Roche AG $10,000.00 07/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211605982
Principal investigator 1 F. Hoffmann-La Roche AG $973.00 07/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211605985
Principal investigator 1 F. Hoffmann-La Roche AG $2,587.00 07/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211605990
Principal investigator 1 Gilead Sciences, Inc. $2,910.60 07/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204642
Principal investigator 1 Bausch Health US, LLC $6,278.58 07/14/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840060
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 07/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114482
Principal investigator 1 Madrigal Pharmaceuticals $8,804.00 07/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246416
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658646
Principal investigator 1 Gilead Sciences, Inc. $500.00 07/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209220
Principal investigator 1 Gilead Sciences, Inc. $60.00 07/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209227
Principal investigator 1 Gilead Sciences, Inc. $87.00 07/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209236
Principal investigator 1 Janssen Research & Development, LLC $239.00 06/30/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193282
Principal investigator 1 Gilead Sciences, Inc. $6,673.50 06/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209041
Principal investigator 1 Gilead Sciences, Inc. $75.00 06/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209112
Principal investigator 1 Gilead Sciences, Inc. $60.00 06/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209173
Principal investigator 1 Gilead Sciences, Inc. $100.00 06/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209179
Principal investigator 1 Gilead Sciences, Inc. $87.00 06/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209197
Principal investigator 1 Janssen Research & Development, LLC $96.25 06/25/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193275
Principal investigator 1 Gilead Sciences, Inc. $100.00 06/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206681
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173996
Principal investigator 1 GlaxoSmithKline, LLC. $2,499.59 06/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173980
Principal investigator 1 Gilead Sciences, Inc. $30.00 06/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204595
Principal investigator 1 Gilead Sciences, Inc. $67.00 06/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204609
Principal investigator 1 Madrigal Pharmaceuticals $490.00 06/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245964
Principal investigator 1 Madrigal Pharmaceuticals $13,979.00 06/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245969
Principal investigator 1 Madrigal Pharmaceuticals $6,417.60 06/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245973
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 06/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245930
Principal investigator 1 Madrigal Pharmaceuticals $3,841.20 06/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245934
Principal investigator 1 Madrigal Pharmaceuticals $2,273.33 06/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245937
Principal investigator 1 Boehringer Ingelheim International GmbH $3,439.80 06/18/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658620
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 06/18/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658622
Principal investigator 1 Gilead Sciences, Inc. $500.00 06/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204617
Principal investigator 1 Gilead Sciences, Inc. $500.00 06/18/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204625
Principal investigator 1 Gilead Sciences, Inc. $7,200.00 06/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206674
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177734
Principal investigator 1 Madrigal Pharmaceuticals $2,478.00 06/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245677
Principal investigator 1 Madrigal Pharmaceuticals $250.00 06/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245680
Principal investigator 1 Gilead Sciences, Inc. $200.00 06/13/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204587
Principal investigator 1 Gilead Sciences, Inc. $790.00 06/13/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209065
Principal investigator 1 Madrigal Pharmaceuticals $6,287.40 06/13/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245633
Principal investigator 1 Janssen Research & Development, LLC $92.13 06/12/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193289
Principal investigator 1 Janssen Research & Development, LLC $92.13 06/12/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193366
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 06/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245554
Principal investigator 1 Bausch Health US, LLC $355.00 06/11/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840094
Principal investigator 1 Gilead Sciences, Inc. $200.00 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209057
Principal investigator 1 Gilead Sciences, Inc. $30.00 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209073
Principal investigator 1 Gilead Sciences, Inc. $130.50 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209088
Principal investigator 1 Gilead Sciences, Inc. $90.00 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209126
Principal investigator 1 Gilead Sciences, Inc. $975.00 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209135
Principal investigator 1 Gilead Sciences, Inc. $43.50 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209152
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209167
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 06/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114476
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173975
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658650
Principal investigator 1 Boehringer Ingelheim International GmbH $8,241.80 05/28/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658632
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 05/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244731
Principal investigator 1 Madrigal Pharmaceuticals $2,435.35 05/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244735
Principal investigator 1 GlaxoSmithKline, LLC. $1,653.14 05/26/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173992
Principal investigator 1 Gilead Sciences, Inc. $60.00 05/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209049
Principal investigator 1 Genentech, Inc. $1,500.00 05/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606089
Principal investigator 1 Madrigal Pharmaceuticals $8,804.00 05/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244369
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 05/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244373
Principal investigator 1 Madrigal Pharmaceuticals $400.00 05/15/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243940
Principal investigator 1 Madrigal Pharmaceuticals $2,277.52 05/15/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243944
Principal investigator 1 Bausch Health US, LLC $4,617.90 05/13/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840090
Principal investigator 1 Janssen Research & Development, LLC $96.25 05/12/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193294
Principal investigator 1 Boehringer Ingelheim International GmbH $1.89 05/09/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658624
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 05/09/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658626
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/09/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658628
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/09/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658630
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173972
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 05/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174896
Principal investigator 1 Gilead Sciences, Inc. $4,733.82 05/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204602
Principal investigator 1 Madrigal Pharmaceuticals $8,271.90 05/05/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243178
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658634
Principal investigator 1 Genentech, Inc. $7,980.00 04/30/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606101
Principal investigator 1 GlaxoSmithKline, LLC. $1,471.50 04/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114509
Principal investigator 1 GlaxoSmithKline, LLC. $9,449.46 04/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174924
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 04/28/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193337
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 04/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242876
Principal investigator 1 Madrigal Pharmaceuticals $1,295.00 04/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242881
Principal investigator 1 Genentech, Inc. $1,054.00 04/25/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606104
Principal investigator 1 Madrigal Pharmaceuticals $1,380.33 04/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242635
Principal investigator 1 Boehringer Ingelheim International GmbH $949.00 04/23/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658636
Principal investigator 1 Boehringer Ingelheim International GmbH $67.34 04/23/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658638
Principal investigator 1 Boehringer Ingelheim International GmbH $67.34 04/23/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658640
Principal investigator 1 Boehringer Ingelheim International GmbH $67.34 04/23/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658642
Principal investigator 1 Boehringer Ingelheim International GmbH $67.34 04/23/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658644
Principal investigator 1 Gilead Sciences, Inc. $1,580.00 04/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209081
Principal investigator 1 Gilead Sciences, Inc. $175.00 04/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209119
Principal investigator 1 Gilead Sciences, Inc. $1,639.00 04/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209143
Principal investigator 1 Gilead Sciences, Inc. $200.00 04/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209158
Principal investigator 1 Gilead Sciences, Inc. $790.00 04/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209187
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 04/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242504
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 04/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242508
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 04/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242512
Principal investigator 1 Madrigal Pharmaceuticals $18,340.00 04/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242516
Principal investigator 1 Madrigal Pharmaceuticals $300.00 04/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242445
Principal investigator 1 Madrigal Pharmaceuticals $6,020.00 04/15/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242417
Principal investigator 1 Genentech, Inc. $2,110.00 04/11/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606109
Principal investigator 1 Madrigal Pharmaceuticals $75.00 04/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242237
Principal investigator 1 Madrigal Pharmaceuticals $710.00 04/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242242
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 04/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242245
Principal investigator 1 Madrigal Pharmaceuticals $4,449.68 04/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242250
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 04/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114498
Principal investigator 1 Bausch Health US, LLC $1,000.00 04/07/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840098
Principal investigator 1 Boehringer Ingelheim International GmbH $225.00 04/07/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658612
Principal investigator 1 Boehringer Ingelheim International GmbH $161.00 04/07/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658614
Principal investigator 1 Genentech, Inc. $21,100.00 04/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606112
Principal investigator 1 Gilead Sciences, Inc. $7,500.00 04/04/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209102
Principal investigator 1 GlaxoSmithKline, LLC. $735.75 04/02/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120827
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658616
Principal investigator 1 Gilead Sciences, Inc. $67.00 04/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204633
Principal investigator 1 Madrigal Pharmaceuticals $4,347.00 04/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241495
Principal investigator 1 Madrigal Pharmaceuticals $75.00 04/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241500
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 04/01/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241505
Principal investigator 1 GlaxoSmithKline, LLC. $114.75 03/31/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120820
Principal investigator 1 Gilead Sciences, Inc. $167.00 03/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204565
Principal investigator 1 Gilead Sciences, Inc. $30.00 03/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204579
Principal investigator 1 GlaxoSmithKline, LLC. $1,698.03 03/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174912
Principal investigator 1 Madrigal Pharmaceuticals $150.00 03/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241222
Principal investigator 1 Madrigal Pharmaceuticals $250.00 03/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241226
Principal investigator 1 Madrigal Pharmaceuticals $2,772.00 03/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241114
Principal investigator 1 Gilead Sciences, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204515
Principal investigator 1 Gilead Sciences, Inc. $67.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204522
Principal investigator 1 Gilead Sciences, Inc. $317.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204529
Principal investigator 1 Gilead Sciences, Inc. $67.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204572
Principal investigator 1 Gilead Sciences, Inc. $1,050.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208944
Principal investigator 1 Gilead Sciences, Inc. $90.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208952
Principal investigator 1 Gilead Sciences, Inc. $790.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208960
Principal investigator 1 Gilead Sciences, Inc. $75.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208968
Principal investigator 1 Gilead Sciences, Inc. $317.50 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208992
Principal investigator 1 Gilead Sciences, Inc. $1,479.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209017
Principal investigator 1 Gilead Sciences, Inc. $100.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209024
Principal investigator 1 Gilead Sciences, Inc. $1,190.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209032
Principal investigator 1 Madrigal Pharmaceuticals $150.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241076
Principal investigator 1 Madrigal Pharmaceuticals $1,239.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241080
Principal investigator 1 Madrigal Pharmaceuticals $775.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241085
Principal investigator 1 Madrigal Pharmaceuticals $490.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241089
Principal investigator 1 Madrigal Pharmaceuticals $200.00 03/19/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248241093
Principal investigator 1 Gilead Sciences, Inc. $60.00 03/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208937
Principal investigator 1 Gilead Sciences, Inc. $75.00 03/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208976
Principal investigator 1 Gilead Sciences, Inc. $75.00 03/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209000
Principal investigator 1 Madrigal Pharmaceuticals $9,097.20 03/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241009
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658594
Principal investigator 1 Boehringer Ingelheim International GmbH $615.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658596
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658598
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658600
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658602
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/12/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658604
Principal investigator 1 Gilead Sciences, Inc. $790.00 03/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208921
Principal investigator 1 Gilead Sciences, Inc. $150.00 03/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208984
Principal investigator 1 Gilead Sciences, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209008
Principal investigator 1 Bausch Health US, LLC $3,850.46 03/11/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840082
Principal investigator 1 Genentech, Inc. $7,385.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606067
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114522
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173988
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174903
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174908
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177717
Principal investigator 1 GlaxoSmithKline, LLC. $877.50 03/07/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177722
Principal investigator 1 Boehringer Ingelheim International GmbH $3,617.86 03/06/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658606
Principal investigator 1 Boehringer Ingelheim International GmbH $210.34 03/06/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658608
Principal investigator 1 Boehringer Ingelheim International GmbH $36.21 03/06/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658610
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 03/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174001
Principal investigator 1 Madrigal Pharmaceuticals $18,340.00 03/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248240159
Principal investigator 1 Madrigal Pharmaceuticals $75.00 03/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240346
Principal investigator 1 Madrigal Pharmaceuticals $4,449.67 03/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240350
Principal investigator 1 Genentech, Inc. $2,110.00 03/05/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606080
Principal investigator 1 Gilead Sciences, Inc. $14,428.80 03/05/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208929
Principal investigator 1 Madrigal Pharmaceuticals $5,751.90 03/03/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248240055
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658618
Principal investigator 1 Boehringer Ingelheim International GmbH $36.21 02/28/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658592
Principal investigator 1 GlaxoSmithKline, LLC. $8,622.25 02/24/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120807
Principal investigator 1 Genentech, Inc. $750.00 02/21/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606053
Principal investigator 1 Madrigal Pharmaceuticals $600.00 02/20/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239871
Principal investigator 1 Janssen Research & Development, LLC $92.13 02/17/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193267
Principal investigator 1 Madrigal Pharmaceuticals $411.60 02/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248239777
Principal investigator 1 Madrigal Pharmaceuticals $150.00 02/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248239781
Principal investigator 1 Madrigal Pharmaceuticals $980.00 02/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248239785
Principal investigator 1 Madrigal Pharmaceuticals $1,295.00 02/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248239789
Principal investigator 1 Madrigal Pharmaceuticals $500.00 02/13/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239697
Principal investigator 1 Genentech, Inc. $3,165.00 02/12/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606075
Principal investigator 1 Madrigal Pharmaceuticals $225.00 02/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239040
Principal investigator 1 Madrigal Pharmaceuticals $710.00 02/06/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239158
Principal investigator 1 Janssen Research & Development, LLC $518.95 02/05/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193304
Principal investigator 1 Janssen Research & Development, LLC $92.13 02/03/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193357
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658648
Principal investigator 1 Genentech, Inc. $16,880.00 01/31/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606063
Principal investigator 1 Gilead Sciences, Inc. $167.00 01/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204502
Principal investigator 1 Gilead Sciences, Inc. $30.00 01/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204540
Principal investigator 1 Gilead Sciences, Inc. $334.00 01/29/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204547
Principal investigator 1 Bausch Health US, LLC $850.00 01/28/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840076
Principal investigator 1 GlaxoSmithKline, LLC. $162.00 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114516
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120794
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192120833
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192173983
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192174900
Principal investigator 1 GlaxoSmithKline, LLC. $114.75 01/28/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177730
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 01/27/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193320
Principal investigator 1 Madrigal Pharmaceuticals $225.00 01/27/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238811
Principal investigator 1 Madrigal Pharmaceuticals $5,964.00 01/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238623
Principal investigator 1 Madrigal Pharmaceuticals $75.00 01/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238627
Principal investigator 1 Madrigal Pharmaceuticals $23,281.29 01/23/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238630
Principal investigator 1 Genentech, Inc. $17,935.00 01/22/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606058
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 01/17/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658588
Principal investigator 1 Genentech, Inc. $2,587.00 01/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606084
Principal investigator 1 Genentech, Inc. $973.00 01/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606093
Principal investigator 1 Genentech, Inc. $10,000.00 01/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211606096
Principal investigator 1 Madrigal Pharmaceuticals $6,300.00 01/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238534
Principal investigator 1 Madrigal Pharmaceuticals $12,040.00 01/17/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238538
Principal investigator 1 Madrigal Pharmaceuticals $1,775.00 01/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238403
Principal investigator 1 Madrigal Pharmaceuticals $1,065.00 01/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238408
Principal investigator 1 Madrigal Pharmaceuticals $75.00 01/16/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238412
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 01/14/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192114490
Principal investigator 1 Bausch Health US, LLC $4,900.42 01/13/2025 Non-covered Recipient Entity
Florida Research Institute LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840086
Principal investigator 1 Boehringer Ingelheim International GmbH $20.65 01/13/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658584
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 01/13/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658586
Principal investigator 1 Genentech, Inc. $15,825.00 01/13/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211606071
Principal investigator 1 Gilead Sciences, Inc. $75.00 01/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204556
Principal investigator 1 Madrigal Pharmaceuticals $1,386.00 01/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238350
Principal investigator 1 Madrigal Pharmaceuticals $350.00 01/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238354
Principal investigator 1 Madrigal Pharmaceuticals $150.00 01/10/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238359
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 01/09/2025 Non-covered Recipient Entity
FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192177738
Principal investigator 1 Janssen Research & Development, LLC $518.95 01/02/2025 Non-covered Recipient Entity
Fl Dgstv Hlth Specialists Llp
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175193349
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Florida Research Institute
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220658590